Literature DB >> 18842709

Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans.

Erika Assarsson1, Huynh-Hoa Bui, John Sidney, Qing Zhang, Jean Glenn, Carla Oseroff, Innocent N Mbawuike, Jeff Alexander, Mark J Newman, Howard Grey, Alessandro Sette.   

Abstract

Continuing antigenic drift allows influenza viruses to escape antibody-mediated recognition, and as a consequence, the vaccine currently in use needs to be altered annually. Highly conserved epitopes recognized by effector T cells may represent an alternative approach for the generation of a more universal influenza virus vaccine. Relatively few highly conserved epitopes are currently known in humans, and relatively few epitopes have been identified from proteins other than hemagglutinin and nucleoprotein. This prompted us to perform a study aimed at identifying a set of human T-cell epitopes that would provide broad coverage against different virus strains and subtypes. To provide coverage across different ethnicities, seven different HLA supertypes were considered. More than 4,000 peptides were selected from a panel of 23 influenza A virus strains based on predicted high-affinity binding to HLA class I or class II and high conservancy levels. Peripheral blood mononuclear cells from 44 healthy human blood donors were tested for reactivity against HLA-matched peptides by using gamma interferon enzyme-linked immunospot assays. Interestingly, we found that PB1 was the major target for both CD4(+) and CD8(+) T-cell responses. The 54 nonredundant epitopes (38 class I and 16 class II) identified herein provided high coverage among different ethnicities, were conserved in the majority of the strains analyzed, and were consistently recognized in multiple individuals. These results enable further functional studies of T-cell responses during influenza virus infection and provide a potential base for the development of a universal influenza vaccine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18842709      PMCID: PMC2593359          DOI: 10.1128/JVI.01563-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

Review 1.  Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism.

Authors:  A Sette; J Sidney
Journal:  Immunogenetics       Date:  1999-11       Impact factor: 2.846

2.  Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles.

Authors:  D L Doolan; S L Hoffman; S Southwood; P A Wentworth; J Sidney; R W Chesnut; E Keogh; E Appella; T B Nutman; A A Lal; D M Gordon; A Oloo; A Sette
Journal:  Immunity       Date:  1997-07       Impact factor: 31.745

3.  The HLA-B14 peptide binding site can accommodate peptides with different combinations of anchor residues.

Authors:  M DiBrino; K C Parker; D H Margulies; J Shiloach; R V Turner; W E Biddison; J E Coligan
Journal:  J Biol Chem       Date:  1994-12-23       Impact factor: 5.157

4.  HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles.

Authors:  D L Doolan; S Southwood; R Chesnut; E Appella; E Gomez; A Richards; Y I Higashimoto; A Maewal; J Sidney; R A Gramzinski; C Mason; D Koech; S L Hoffman; A Sette
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

5.  CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch.

Authors:  Deborah M Brown; Allison M Dilzer; Dana L Meents; Susan L Swain
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

6.  Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes.

Authors:  C C Wilson; B Palmer; S Southwood; J Sidney; Y Higashimoto; E Appella; R Chesnut; A Sette; B D Livingston
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

7.  HLA-A1 and HLA-A3 T cell epitopes derived from influenza virus proteins predicted from peptide binding motifs.

Authors:  M DiBrino; T Tsuchida; R V Turner; K C Parker; J E Coligan; W E Biddison
Journal:  J Immunol       Date:  1993-12-01       Impact factor: 5.422

8.  Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays.

Authors:  A Sette; J Sidney; M F del Guercio; S Southwood; J Ruppert; C Dahlberg; H M Grey; R T Kubo
Journal:  Mol Immunol       Date:  1994-08       Impact factor: 4.407

9.  Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia.

Authors:  L G Rudenko; A N Slepushkin; A S Monto; A P Kendal; E P Grigorieva; E P Burtseva; A R Rekstin; A L Beljaev; V E Bragina; N Cox
Journal:  J Infect Dis       Date:  1993-10       Impact factor: 5.226

10.  Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide.

Authors:  S Tangri; G Y Ishioka; X Huang; J Sidney; S Southwood; J Fikes; A Sette
Journal:  J Exp Med       Date:  2001-09-17       Impact factor: 14.307

View more
  109 in total

1.  CD4+ T cells limit the damage in influenza.

Authors:  Anne Kelso
Journal:  Nat Med       Date:  2012-02-06       Impact factor: 53.440

2.  Use of replication restricted recombinant vesicular stomatitis virus vectors for detection of antigen-specific T cells.

Authors:  Nelson B Moseley; Oskar Laur; Chris C Ibegbu; Gilbert D Loria; Gini Ikwuenzunma; Himangi R Jayakar; Michael A Whitt; John D Altman
Journal:  J Immunol Methods       Date:  2011-10-08       Impact factor: 2.303

Review 3.  Progress on adenovirus-vectored universal influenza vaccines.

Authors:  Kui Xiang; Guan Ying; Zhou Yan; Yan Shanshan; Zhang Lei; Li Hongjun; Sun Maosheng
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Positive Selection in CD8+ T-Cell Epitopes of Influenza Virus Nucleoprotein Revealed by a Comparative Analysis of Human and Swine Viral Lineages.

Authors:  Heather M Machkovech; Trevor Bedford; Marc A Suchard; Jesse D Bloom
Journal:  J Virol       Date:  2015-08-26       Impact factor: 5.103

Review 5.  Traditional and new influenza vaccines.

Authors:  Sook-San Wong; Richard J Webby
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

Review 6.  Antigens for CD4 and CD8 T cells in tuberculosis.

Authors:  Cecilia S Lindestam Arlehamn; David Lewinsohn; Alessandro Sette; Deborah Lewinsohn
Journal:  Cold Spring Harb Perspect Med       Date:  2014-05-22       Impact factor: 6.915

7.  Flow Cytometric and Cytokine ELISpot Approaches To Characterize the Cell-Mediated Immune Response in Ferrets following Influenza Virus Infection.

Authors:  Anthony DiPiazza; Katherine Richards; Frances Batarse; Laura Lockard; Hui Zeng; Adolfo García-Sastre; Randy A Albrecht; Andrea J Sant
Journal:  J Virol       Date:  2016-08-12       Impact factor: 5.103

8.  Influenza B virus-specific CD8+ T-lymphocytes strongly cross-react with viruses of the opposing influenza B lineage.

Authors:  Carolien E van de Sandt; YingYing Dou; Stella E Vogelzang-van Trierum; Kim B Westgeest; Mark R Pronk; Albert D M E Osterhaus; Ron A M Fouchier; Guus F Rimmelzwaan; Marine L B Hillaire
Journal:  J Gen Virol       Date:  2015-04-21       Impact factor: 3.891

9.  Protection by universal influenza vaccine is mediated by memory CD4 T cells.

Authors:  Sophie A Valkenburg; Olive T W Li; Athena Li; Maireid Bull; Thomas A Waldmann; Liyanage P Perera; Malik Peiris; Leo L M Poon
Journal:  Vaccine       Date:  2018-06-07       Impact factor: 3.641

10.  Preemptive priming readily overcomes structure-based mechanisms of virus escape.

Authors:  Sophie A Valkenburg; Stephanie Gras; Carole Guillonneau; Lauren A Hatton; Nicola A Bird; Kelly-Anne Twist; Hanim Halim; David C Jackson; Anthony W Purcell; Stephen J Turner; Peter C Doherty; Jamie Rossjohn; Katherine Kedzierska
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.